Bristol-Myers Squibb Co
(BMY-NYSE)
DRUGS - Drug Manufacturers - Major
Stock report updated on 01/20/2012
- With a 26.4% return in the past year, this stock outperformed 90 percent of stocks in the S&P-100.
- BMY is one of this month's worst performers with a return of -6.8%, underperforming 90 percent of stocks in the S&P-100.
- Down 4.3%, BMY is one of this week's biggest decliners.
- The price of this low-beta stock is expected to increase by 0.42% for every 1% increase in the S&P-500.
- Volatility is forecast to fall over the next month.
- With RSI < 30, BMY is oversold. Odds slightly favor a short-term price reversal.
- Price crossed below 50-day moving average this week - a bearish signal.
| Closing price: |
$32.65 |
| Support price level: |
$29.01 |
| Resistance price level: |
$33.22 |
| Relative strength index (14-day RSI): |
19.0 |
| Beta: |
0.42 |
52-Week Range
| Low |
High |
Price as % of Range |
| $24.97 |
$35.29 |
77.5% |
Moving Averages
| 200 day |
50 day |
20 day |
10 day |
| $30.23 |
$33.10 |
$34.37 |
$33.76 |
Volatility (annualized std. dev.)
Historical
(5 year) |
Last month |
Current estimate |
Next month forecast |
| 26.8% |
15.3% |
26.0% |
25.7% |
Value at Risk
There is an estimated 5% probability that the stock price of Bristol-Myers Squibb Co will fall by more than:
- 7.1% in the next week.
- 14.5% in the next month.
- 39.6% in the next year.
Company News for Bristol-Myers Squibb Co
Google Finance |
MSN Money |
Reuters
Reports for Other Stocks
